Dyadic International Inc
NASDAQ:DYAI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.985
2.27
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Dyadic International Inc
Dyadic International Inc
Cash Taxes Paid
Dyadic International Inc
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dyadic International Inc
NASDAQ:DYAI
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Taxes Paid
$1.6B
|
CAGR 3-Years
47%
|
CAGR 5-Years
129%
|
CAGR 10-Years
84%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Dyadic International Inc
Glance View
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 7 full-time employees. The company went IPO on 2004-11-05. The firm is focused on developing C1 platform for use in human and animal pharmaceutical applications across the world. The C1 platform technology is based on the Myceliopthora thermophila fungus, which the Company named it as C1. The C1 gene expression platform is used in the discovery, development and manufacturing of biologic medicines and vaccines. The C1 technology is a fungal expression system for gene discovery, development, and production of enzymes and other proteins. The C1 technology is commercially available solutions to uptake genes and develop industrial processes to produce volumes of enzymes and other protein products. The firm is also working on COVID-19 related vaccine and antibody opportunities, including COVID-19 vaccine candidate, DYAI-100.
You don't have any saved screeners yet
